Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Frederic Colombel

Showing results (251-260 of 377) with videos related to

Pageof 38
Sort By:
Arxiv|August 30, 2023
Unraveling the Link between Periodontitis and Inflammatory Bowel Disease: Challenges and OutlookHimanshi Tanwar, Jeba Mercy Gnanasekaran, Devon Allison, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Gut Microbes|February 7, 2025
Alterations in mucosa branched <i>N</i>-glycans lead to dysbiosis and downregulation of ILC3: a key driver of intestinal inflammationCláudia S Rodrigues, Joana Gaifem, Márcia S Pereira, et al.
The American Journal of Gastroenterology|December 1, 2007
Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and predictionPeggy Vandewalle-El Khoury, Jean-Frederic Colombel, Sofie Joossens, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|January 3, 2018
Thiopurines in Inflammatory Bowel Disease: New Findings and PerspectivesNanne K H de Boer, Laurent Peyrin-Biroulet, Bindia Jharap, et al.
Digestive Diseases and Sciences|July 15, 2021
Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching AnalysisEun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, et al.
Gastroenterology|July 17, 2007
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006Michael Clark, Jean-Frederic Colombel, Brian C Feagan, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 studySilvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.
Pageof 38

Showing results (251-260 of 377) with videos related to

Sort By:
Pageof 38
Arxiv|August 30, 2023
Unraveling the Link between Periodontitis and Inflammatory Bowel Disease: Challenges and OutlookHimanshi Tanwar, Jeba Mercy Gnanasekaran, Devon Allison, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Gut Microbes|February 7, 2025
Alterations in mucosa branched <i>N</i>-glycans lead to dysbiosis and downregulation of ILC3: a key driver of intestinal inflammationCláudia S Rodrigues, Joana Gaifem, Márcia S Pereira, et al.
The American Journal of Gastroenterology|December 1, 2007
Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and predictionPeggy Vandewalle-El Khoury, Jean-Frederic Colombel, Sofie Joossens, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|January 3, 2018
Thiopurines in Inflammatory Bowel Disease: New Findings and PerspectivesNanne K H de Boer, Laurent Peyrin-Biroulet, Bindia Jharap, et al.
Digestive Diseases and Sciences|July 15, 2021
Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching AnalysisEun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, et al.
Gastroenterology|July 17, 2007
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006Michael Clark, Jean-Frederic Colombel, Brian C Feagan, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 studySilvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.
Pageof 38